. 2024 Apr 16;34(10):6488–6498. doi: 10.1007/s00330-024-10652-4

Table 3.

Relative performance of [⁶⁸Ga]DOTATATE PET/CT compared to other imaging modalities in detecting number of lesions per patient

No. of participants	[⁶⁸ Ga]DOTATATE PET/CT
[¹⁸F]FDG PET/CT	26/41 (63.4%, 46.9–77.9%)	14/41 (34.2%, 20.1–50.6)	1/41 (2.4%, 0.1–12.9%)	40/41 (97.6%, 87.1–99.9%)
MRI of the spine	27/41 (65.9%, 49.4–79.9%)	14/41 (34.2%, 20.1–50.6)	0/41 (0.0%, 0.0–8.6%)	41/41 (100%, 91.4–100.0%)
Whole-body MRI	21/23 (91.3%, 72.0–98.9%)	2/23 (8.7%, 1.1–28.0%)	0/23 (0.0%, 0.0–14.8%)	23/23 (100%, 85.2–100.0%)
Whole-body CT	28/33 (84.8%, 68.1–94.9%)	5/33 (15.2%, 5.1–31.9%)	0/33 (0.0%, 0.0–10.6%)	33/33 (100%, 89.4–100.0%)

No. of participants

[⁶⁸ Ga]DOTATATE PET/CT

Greater

Equal

Lesser

Greater or equal

[¹⁸F]FDG PET/CT

26/41

(63.4%, 46.9–77.9%)

14/41

(34.2%, 20.1–50.6)

1/41

(2.4%, 0.1–12.9%)

40/41

(97.6%, 87.1–99.9%)

MRI of the spine

27/41

(65.9%, 49.4–79.9%)

14/41

(34.2%, 20.1–50.6)

0/41

(0.0%, 0.0–8.6%)

41/41

(100%, 91.4–100.0%)

Whole-body MRI

21/23

(91.3%, 72.0–98.9%)

2/23

(8.7%, 1.1–28.0%)

0/23

(0.0%, 0.0–14.8%)

23/23

(100%, 85.2–100.0%)

Whole-body CT

28/33

(84.8%, 68.1–94.9%)

5/33

(15.2%, 5.1–31.9%)

0/33

(0.0%, 0.0–10.6%)

33/33

(100%, 89.4–100.0%)

Values in the table are expressed in ratios, defined as the number of participants of [⁶⁸Ga]DOTATATE PET/CT detecting greater, equal, lesser, and greater or equal number of lesions per participant compared to [¹⁸F]FDG PET/CT, MRI of the spine, contrast-enhanced whole-body MRI, and contrast-enhanced CT. In parentheses are the percentages along with 95% confidence intervals